How to take Rucaparib

Before patients are treated with Rucaparib (Rucaparib), doctors will select eligible patients for drug maintenance treatment based on the presence of harmful BRC mutations (germline and/or somatic). A negative result from a plasma sample does not mean that the patient's tumor is negative for BRCA mutations. If results from plasma specimens are negative, consider further genomic testing using clinically indicated tumor specimens.

Patients receiving rucaparib for metastatic castration-resistant prostate cancer should also receive concomitant treatment with a gonadotropin-releasing hormone (GnRH) analogue or should undergo bilateral orchiectomy. The recommended dose of rucapanib for the treatment of ovarian cancer and prostate cancer is 600 mg (two 300 mg tablets), taken twice daily, with or without food, for a total daily dose of 1200 mg; treatment is continued until disease progression or unacceptable toxicity occurs. To control adverse effects, consider interrupting treatment with rucapanib or reducing its dose. The starting dose of rucaparib is 600 mg twice daily, with the first dose reduced to 500 mg twice daily, the second dose reduced to 400 mg twice daily, and the third dose reduced to 300 mg twice daily.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).